These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 31219366)

  • 21. Acquired factor VIII inhibitor in an HIV-infected patient after treatment with pegylated interferon-alpha 2a and ribavirin.
    Paul S; Javed U; Tevendale R; Lanford J; Liu R
    AIDS; 2007 Mar; 21(6):784-5. PubMed ID: 17413709
    [No Abstract]   [Full Text] [Related]  

  • 22. The multifaceted functions of ribavirin: antiviral, immunomodulator, or both?
    Mondelli MU
    Hepatology; 2014 Oct; 60(4):1126-9. PubMed ID: 24753082
    [No Abstract]   [Full Text] [Related]  

  • 23. Older age per se has negative effect on hepatitis C patients treated with peginterferon and ribavirin.
    Chen TM; Tung JN
    Am J Gastroenterol; 2009 Aug; 104(8):2117-9. PubMed ID: 19661945
    [No Abstract]   [Full Text] [Related]  

  • 24. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation.
    Ueda Y; Takada Y; Marusawa H; Egawa H; Uemoto S; Chiba T
    Transplantation; 2010 Sep; 90(6):661-5. PubMed ID: 20110853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefit of pegylated interferon-alpha-2a/ribavirin in a patient with common variable immunodeficiency and hepatitis C virus cirrhosis after liver transplantation and splenic embolization.
    Foruny JR; Bárcena R; Moreno A; Blázquez J; Manzano R; Gil-Grande LA; Moreno A; Nuño J
    Transplantation; 2006 Jul; 82(2):289-90. PubMed ID: 16858295
    [No Abstract]   [Full Text] [Related]  

  • 26. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S
    Transplant Proc; 2005 Dec; 37(10):4403-5. PubMed ID: 16387131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients.
    Medrano J; Barreiro P; Resino S; Tuma P; Rodríguez V; Vispo E; Labarga P; Madejón A; García-Samaniego J; Jiménez-Nácher I; Martín-Carbonero L; Soriano V
    Clin Infect Dis; 2009 Nov; 49(9):1397-401. PubMed ID: 19814621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection.
    Mahajan S; Avasthi A; Grover S; Chawla YK
    J Psychosom Res; 2014 Aug; 77(2):109-15. PubMed ID: 25077851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.
    Mukherjee S; Rogge J; Weaver L; Schafer DF
    Transplant Proc; 2003 Dec; 35(8):3042-4. PubMed ID: 14697974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seventy-two weeks of peginterferon and ribavirin for patients with partial early virologic response?
    Hoefs JC; Morgan TR
    Hepatology; 2007 Dec; 46(6):1671-4. PubMed ID: 18046713
    [No Abstract]   [Full Text] [Related]  

  • 32. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy.
    Kraus MR; Schäfer A; Faller H; Csef H; Scheurlen M
    J Clin Psychiatry; 2003 Jun; 64(6):708-14. PubMed ID: 12823087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C.
    Martín-Santos R; Díez-Quevedo C; Castellví P; Navinés R; Miquel M; Masnou H; Soler A; Ardevol M; García F; Galeras JA; Planas R; Solà R
    Aliment Pharmacol Ther; 2008 Feb; 27(3):257-65. PubMed ID: 17988237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study.
    Ide K; Sato I; Imai T; Hawke P; Yamada H; Kawasaki Y; Masaki N
    Biol Pharm Bull; 2016 Dec; 39(12):2060-2065. PubMed ID: 27645378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PegIFN/ribavirin during acute HCV coinfection.
    Bernard EJ
    IAPAC Mon; 2004 Jul; 10(7):260-1. PubMed ID: 15624247
    [No Abstract]   [Full Text] [Related]  

  • 36. Multimethod assessment of baseline depression and relationship to hepatitis C treatment discontinuation.
    Weiss JJ; Prieto S; Bräu N; Dieterich DT; Marcus SM; Stivala A; Gorman JM
    Int J Psychiatry Med; 2018 Jul; 53(4):256-272. PubMed ID: 29298535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.
    Sockalingam S; Balderson K
    Int Clin Psychopharmacol; 2005 Sep; 20(5):289-90. PubMed ID: 16096520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Celiac disease in chronic hepatitis C patients under pegylated-interferon plus ribavirin treatment. Preliminary results of a prospective single center study.
    Elefsiniotis IS; Fotos NV; Pantazis KD; Papadeli D; Mavrogiannis C
    Hepatogastroenterology; 2007; 54(75):2 p preceding table of contents. PubMed ID: 17591034
    [No Abstract]   [Full Text] [Related]  

  • 39. Acute exacerbation among chronic hepatitis C patients: tip of the iceberg that deserves more attention.
    Wong RJ; Cheung RC
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1181-2. PubMed ID: 23735449
    [No Abstract]   [Full Text] [Related]  

  • 40. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.